이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

MAPT 프로토콜: 고관절 골절 후 조기 회복을 위한 고정술 대 관절성형술 수술 치료(FASTER-HIP) (FASTER-HIP)

2026년 11월 5일 업데이트: Joseph Patterson, University of Southern California

근골격계 적응형 플랫폼 시험(MAPT): 고관절 골절 후 조기 회복을 위한 고정술 대 관절성형술 수술 치료(FASTER-HIP)

This study is an intervention domain of the Musculoskeletal Adaptive Platform Trial. The primary goal of this pragmatic, randomized, open-label, comparative effectiveness trial is to evaluate if arthroplasty is superior to internal fixation when used to treat minimally displaced femoral neck fractures in older adults ≥60 years old. We hypothesize that arthroplasty will reduce death, preserve ambulation, increase days alive and out of hospital, and improve health status compared to internal fixation within 4 months and 12 months from randomization.

연구 개요

상세 설명

The Musculoskeletal Adaptive Platform Trial (MAPT) is an adaptive platform trial protocol that enables the simultaneous evaluation of multiple interventions (i.e., intervention domains) within a consistent infrastructure. Each intervention being evaluated in the MAPT will have an intervention domain protocol that describes additional eligibility criteria, interventions, secondary outcomes, and statistical stopping rules. The overarching objective of the MAPT trial platform is to incrementally decrease decisional uncertainty and identify treatments that will optimize patient outcomes. The platform focuses on the comparative effectiveness of available treatment options.

Adult patients aged 60 years or older with a low-energy minimally displaced femoral neck fracture treated with surgery are eligible for the FASTER-HIP intervention domain. Nearly half of all elderly hip fractures are femoral neck fractures, and approximately 20% are minimally displaced. Internal fixation has remained the treatment of choice for these injuries because these fractures can be fixed in situ, and the surgical implants can be inserted with little surgical dissection. Patients treated with internal fixation experience high complication rates, with the pooled risk of reoperation and mortality each above 14%. Preliminary data have suggested arthroplasty for minimally displaced fractures may lead to better patient outcomes, including improved ambulation, fewer reoperations, and a lower risk of death compared to internal fixation. While the preliminary data supporting the use of arthroplasty for minimally displaced fractures is promising, the necessary evidence to make this practice change remains lacking.

FASTER-HIP is a pragmatic, randomized, open-label, comparative effectiveness trial comparing hip arthroplasty versus internal fixation for minimally displaced femoral neck fractures. Randomization in this domain occurs in a 1:1 ratio (hip arthroplasty:internal fixation). The primary outcome is a composite of death within 120 days, ambulation status at 120 days, and days alive and out of hospital within 120 days of randomization. The primary outcome will be hierarchically assessed using the Win ratio. Secondary outcomes include the same composite at 365 days, individual components of the composite, health-related quality of life (EQ-5D-5L), and pain scores during hospitalization.

연구 유형

중재적

등록 (추정된)

600

단계

  • 해당 없음

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 장소

      • Grålum, 노르웨이, 1714
        • 모병
        • Sykehuset Østfold HF / Østfold Hospital Trust
        • 연락하다:
          • Frede Frihagen, MD
        • 연락하다:
        • 수석 연구원:
          • Frede Frihagen, MD
    • California
      • Irvine, California, 미국, 92660
        • 모병
        • University of California, Irvine
        • 수석 연구원:
          • Gerard Slobogean, MD
        • 연락하다:
      • Los Angeles, California, 미국, 90048
        • 모병
        • Cedars-Sinai Medical Center
        • 수석 연구원:
          • Carol Lin, MD
        • 연락하다:
      • Los Angeles, California, 미국, 90033
        • 모병
        • University of Southern California
        • 수석 연구원:
          • Joshua L Gary, MD
        • 연락하다:
      • Los Angeles, California, 미국, 90033
        • 모병
        • Los Angeles General Medical Center
        • 수석 연구원:
          • Joshua L Gary, MD
        • 연락하다:
      • San Francisco, California, 미국, 94143
        • 모병
        • University of California San Francisco
        • 수석 연구원:
          • Saam Morshed, MD
        • 연락하다:
    • Florida
      • Miami, Florida, 미국, 33146
        • 아직 모집하지 않음
        • University of Miami
        • 연락하다:
        • 수석 연구원:
          • Giselle Hernandez, MD
    • Indiana
      • Bloomington, Indiana, 미국, 47405
        • 모병
        • Indiana University
        • 수석 연구원:
          • Dillon O'Neill, MD
        • 연락하다:
    • Maryland
      • Baltimore, Maryland, 미국, 21201
        • 모병
        • University of Maryland, Baltimore - R Adams Cowley Shock Trauma Center
        • 수석 연구원:
          • Mark Gage, MD
        • 연락하다:
      • Largo, Maryland, 미국, 20774
        • 모병
        • University of Maryland Capital Region Health
        • 수석 연구원:
          • Todd Jaeblon, MD
        • 연락하다:
    • Massachusetts
      • Boston, Massachusetts, 미국, 02215
        • 아직 모집하지 않음
        • Beth Israel Deaconess Medical Center
        • 연락하다:
        • 수석 연구원:
          • Ishaq Ibrahim, MD
      • Boston, Massachusetts, 미국, 02115
        • 모병
        • Massachusetts General Brigham
        • 연락하다:
        • 수석 연구원:
          • Michael Weaver, MD
    • Mississippi
      • University, Mississippi, 미국, 38677
        • 모병
        • University of Mississippi
        • 수석 연구원:
          • Patrick Bergin, MD
        • 연락하다:
    • New York
      • New York, New York, 미국, 10016
    • Ohio
      • Cincinnati, Ohio, 미국, 45221
        • 모병
        • University of Cincinnati
        • 연락하다:
        • 수석 연구원:
          • Michael Beltran, MD
    • Oklahoma
      • Oklahoma City, Oklahoma, 미국, 73104
        • 모병
        • University of Oklahoma Health Sciences Center
        • 수석 연구원:
          • Brandon Hull, MD
        • 연락하다:
    • Pennsylvania
      • Allentown, Pennsylvania, 미국, 18102
        • 모병
        • St. Luke's University Health System
        • 수석 연구원:
          • Dustin Greenhill, MD
        • 연락하다:
    • South Carolina
      • Greenville, South Carolina, 미국, 29601
    • Tennessee
      • Nashville, Tennessee, 미국, 37235
        • 모병
        • Vanderbilt University
        • 연락하다:
        • 수석 연구원:
          • Lauren Tatman, MD
    • Utah
      • Salt Lake City, Utah, 미국, 84108
        • 모병
        • University of Utah
        • 수석 연구원:
          • Lucas Marchand, MD
        • 연락하다:
    • Vermont
      • Burlington, Vermont, 미국, 05405
        • 아직 모집하지 않음
        • University of Vermont
        • 연락하다:
        • 수석 연구원:
          • Michael Blankstein, MD
    • Virginia
      • Fairfax, Virginia, 미국, 22031
        • 모병
        • Inova Health Care Services
        • 수석 연구원:
          • Greg Gaski, MD
        • 연락하다:
    • Wisconsin
      • Madison, Wisconsin, 미국, 53706
        • 모병
        • University of Wisconsin - Madison
        • 수석 연구원:
          • Chris Domes, MD
        • 연락하다:
      • Barcelona, 스페인
        • 아직 모집하지 않음
        • Hospital Universitari Vall d'Hebron
        • 연락하다:
        • 수석 연구원:
          • Carlos Alberto Piedra-Calle, MD
      • Barcelona, 스페인
        • 아직 모집하지 않음
        • Consorci Sanitari de l'Alt Penedès i Garraf (CSAPG)
        • 수석 연구원:
          • Alfred Dealbert, MD
        • 연락하다:
      • Barcelona, 스페인, 08221
        • 아직 모집하지 않음
        • Hospital Universitario Mutua de Terrassa
        • 연락하다:
        • 수석 연구원:
          • Pablo Castillon Bernal, MD
      • Barcelona, 스페인
        • 아직 모집하지 않음
        • FRCB-IDIBAPS (Hospital Clinic Barcelona)
        • 연락하다:
        • 수석 연구원:
          • Pilar Camacho, MD
      • Edinburgh, 영국, EH8 8BG
      • Ottawa, 캐나다, K1H 8L6
        • 아직 모집하지 않음
        • The Ottawa Hospital
        • 연락하다:
        • 수석 연구원:
          • Bradley Meulenkamp, MD
    • British Columbia
      • Vancouver, British Columbia, 캐나다, V6T 1Z4
        • 모병
        • University of British Columbia
        • 연락하다:
          • Aresh Sepehri, MD
        • 연락하다:
        • 수석 연구원:
          • Aresh Sephri, MD
      • Vancouver, British Columbia, 캐나다
        • 모병
        • Fraser Health Authority
        • 연락하다:
        • 연락하다:
          • 전화번호: 604-777-5577
        • 수석 연구원:
          • Darius Viskontas, MD
    • Ontario
      • London, Ontario, 캐나다, N6A 5W9,
        • 모병
        • London Health Sciences Centre
        • 연락하다:
        • 수석 연구원:
          • Emil Schemitsch, MD

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

60년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • 60 years of age or older undergoing surgery due to a minimally displaced femoral neck fracture
  • The patient has a health condition affecting physical mobility.
  • Complete fracture of the femoral neck (AO/OTA 31B) confirmed with anteroposterior and lateral hip radiographs, computed tomography, or magnetic resonance imaging.
  • Minimally displaced fracture that could be, in the judgment of the attending surgeon, managed with either arthroplasty or in situ internal fixation without reduction.
  • Low energy injury mechanism.
  • Surgeons with expertise in internal fixation and total hip arthroplasty or hemiarthroplasty are available to perform surgery.

Exclusion Criteria:

  • The patient is not clinically suitable for either compared treatment.
  • Expected injury survival of less than 12 months.
  • Terminal illness with expected survival of less than 12 months.
  • Incarceration.
  • Unable to obtain informed consent due to language barriers.
  • Unable to obtain informed consent because the legally authorized representative was unavailable.
  • Problems, in the judgment of the study personnel, with maintaining follow-up with the patient.
  • Currently enrolled in a study or intervention domain that does not permit co-enrollment.
  • Prior enrollment in the specific platform trial intervention domain.
  • Patient or legally authorized representative did not provide informed consent (declined participation).
  • Eligible patient or legally authorized representative was not approached within the screening window (missed participant).
  • Other reasons to exclude the patient, as approved by the data coordinating center.
  • Associated lower extremity injury that prevents post-operative weight-bearing.
  • Retained hardware around the hip that precludes either study treatment.
  • Infection around the hip (soft tissue or bone).
  • Pathologic fracture with a lytic lesion in the femoral neck that precludes internal fixation.
  • Injury did not occur within 21 days of screening.
  • Patient is too ill, in the judgment of the attending surgeon, for internal fixation.
  • Patient is too ill, in the judgment of the attending surgeon, for arthroplasty.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
활성 비교기: 고관절 치환술

Participants will undergo surgical treatment using standard hip arthroplasty techniques for femoral minimally displaced femoral neck fracture. A modern porous-coated press-fit or cemented hip arthroplasty prosthesis will be used at the treating surgeon's discretion. Press-fit implants that have no ingrowth or ongrowth surface will not be permitted. The type of hip prosthesis (hemiarthroplasty or total hip arthroplasty), bearing (single or dual mobility), or the method of arthroplasty fixation (cemented or uncemented) will be at the discretion of the treating surgeon.

활성 비교기: 내고정

Participants will undergo surgical treatment using standard fixation techniques for minimally displaced femoral neck fractures. The treating surgeon may perform fracture reduction maneuvers if desired. Fixed-angle devices and multiple screws will be permitted. The internal fixation device(s) will be inserted through a small lateral incision. Internal fixation constructs combining cancellous screws and fixed-angle devices will be permitted.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Composite outcome of death, ambulation status, and days alive and out of hospital.
기간: 120 days after randomization

Death consists of time to all-cause mortality.

Ambulation will be evaluated using an ordinal ranking of independence.

Days alive and out of hospital will be calculated by subtracting the sum of days meeting one of two criteria below:

  • Days not alive.
  • Any day on which the participant had an overnight stay in a hospital, inpatient rehabilitation, skilled nursing facility, nursing home, inpatient mental health care facility, or long-term care facility.
120 days after randomization

2차 결과 측정

결과 측정
측정값 설명
기간
Composite outcome of death, ambulation status, and days alive and out of hospital.
기간: 365 days after randomization

Death consists of time to all-cause mortality.

Ambulation will be evaluated using an ordinal ranking of independence.

Days alive and out of hospital will be calculated by subtracting the sum of days meeting one of two criteria below:

  • Days not alive.
  • Any day on which the participant had an overnight stay in a hospital, inpatient rehabilitation, skilled nursing facility, nursing home, inpatient mental health care facility, or long-term care facility.
365 days after randomization
Death
기간: 120 days post-randomization

Death consists of time to all-cause mortality.

120 days post-randomization
Death
기간: 12 months post-randomization

Death consists of time to all-cause mortality.

12 months post-randomization
Ambulation status
기간: 120 days post-randomization

Ambulation will be evaluated using an ordinal ranking of independence

120 days post-randomization
Ambulation status
기간: 12 months post-randomization

Ambulation will be evaluated using an ordinal ranking of independence

12 months post-randomization
Days alive and out of hospital
기간: 120 days post-randomization

Days alive and out of hospital will be calculated by subtracting the sum of days meeting one of two criteria below:

  • Days not alive.
  • Any day on which the participant had an overnight stay in a hospital, inpatient rehabilitation, skilled nursing facility, nursing home, inpatient mental health care facility, or long-term care facility.
120 days post-randomization
Days alive and out of hospital
기간: 12 months post-randomization

Days alive and out of hospital will be calculated by subtracting the sum of days meeting one of two criteria below:

  • Days not alive.
  • Any day on which the participant had an overnight stay in a hospital, inpatient rehabilitation, skilled nursing facility, nursing home, inpatient mental health care facility, or long-term care facility.
12 months post-randomization
Health-related quality of life
기간: 120 days days post-randomization

EQ-5D-5L - Range: 0 to 1, Higher scores indicates better self-perceived health

120 days days post-randomization
Health-related quality of life
기간: 12 months post-randomization

EQ-5D-5L - Range: 0 to 1, Higher scores indicates better self-perceived health

12 months post-randomization
Numeric Pain Rating Scale
기간: During hospitalization in the first seven postoperative days

The highest level of pain recorded daily in the participant's medical record - Range: 0-10, higher score indicates higher level of pain

During hospitalization in the first seven postoperative days

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 수석 연구원: Joseph T Patterson, MD, University of Southern California

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2026년 1월 23일

기본 완료 (추정된)

2029년 2월 28일

연구 완료 (추정된)

2030년 1월 31일

연구 등록 날짜

최초 제출

2025년 10월 31일

QC 기준을 충족하는 최초 제출

2025년 11월 19일

처음 게시됨 (실제)

2025년 11월 24일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 10일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 5일

마지막으로 확인됨

2026년 6월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

미정

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다